Company Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program.
The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio.
Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | James Caruso |
Contact Details
Address: 100 Campus Drive Florham Park, New Jersey 07932 United States | |
| Phone | 608 441 8120 |
| Website | cellectar.com |
Stock Details
| Ticker Symbol | CLRB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001279704 |
| CUSIP Number | 15117F880 |
| ISIN Number | US15117F8804 |
| Employer ID | 04-3321804 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James V. Caruso | President, Chief Executive Officer and Director |
| Chad J. Kolean CPA | Vice President, Chief Financial Officer and Secretary |
| Jarrod Longcor | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 19, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 18, 2026 | PRE 14A | Other preliminary proxy statements |
| May 18, 2026 | 8-K | Current Report |
| May 14, 2026 | 8-K | Current Report |
| May 14, 2026 | 10-Q | Quarterly Report |
| May 11, 2026 | SCHEDULE 13G | Filing |
| May 8, 2026 | 8-K | Current Report |
| May 6, 2026 | 424B5 | Filing |
| Apr 30, 2026 | 10-K/A | [Amend] Annual report |
| Mar 4, 2026 | 8-K | Current Report |